On August 12, 2014, the Department of Pulmonary Circulation successfully treated a patient with severe pulmonary hypertension with a subcutaneous rimodulin micropump, pioneering the subcutaneous treatment of critically ill patients with class III-IV cardiac function! The patient was admitted to the hospital one month ago with severe pulmonary hypertension and severe right heart failure and was critically ill, and his family was distraught. Two weeks ago, the patient was placed subcutaneously on an injectable rimodulin micropump and gradually rimodulin was increased to 17.5 ng/kg.min, which gradually led to the miracle of life. The patient’s heart failure index NT-proBNP dropped dramatically by 3000 pg/ml, edema subsided, vital signs gradually returned to normal, and the patient was discharged from the hospital in good condition. After Beijing Fu Wai Cardiovascular Hospital, our pulmonary circulation department became the second specialized center in China to apply subcutaneous injection of rimodulin for the treatment of pulmonary hypertension, which also brings a new gospel for severe pulmonary hypertension. Note: New developments in the treatment of pulmonary hypertension with Treprostinil (rimodulin) Epoprostenol was once the “ultimate weapon” in the treatment of pulmonary hypertension, but it has a short half-life of 3-5 minutes and cannot be administered orally, but only continuously through the central vein. The risks of central venous catheter infection and critical pulmonary hypertension due to drug discontinuation have prompted the search for new prostacyclin analogues with long half-lives and convenient routes of administration. Treprostacyclin is a stable prostacyclin analogue with a half-life of approximately 80 minutes when administered subcutaneously. Treprostinil can be administered continuously subcutaneously via a small subcutaneous micropump. A multicenter, randomized, placebo-controlled, double-blind study of treprostinil by Simonneau et al. showed that treprostinil was effective in improving signs, symptoms, and hemodynamic parameters in patients with pulmonary hypertension in cardiac function class II or higher. The study was followed by further clinical studies. Subsequent clinical studies have further demonstrated that treprostinil is an effective treatment for pulmonary hypertension, with subcutaneous injection of treprostinil approved for the treatment of pulmonary hypertension in the United States in 2002, in the European Union in 2006, and in China this year for the treatment of Chinese patients with pulmonary hypertension.